Abstract
Get full access to this article
View all access options for this article.
References
1.
Nervo
A
,
Ragni
A
,
Gallo
M
,
Ferraris
A
,
Fonio
P
,
Piovesan
A
,
Arvat
E
. 2020 . Symptomatic biliary disorders during lenvatinib treatment for thyroid cancer: an underestimated problem . Thyroid , 30 :229 –236 .
2.
Aydemirli
MD
,
Kapiteijn
E
,
Ferrier
KRM
,
Ottevanger
PB
,
Links
TP
,
van der Horst-Schrivers
ANA
,
Broekman
KE
,
Groenwold
RHH
,
Zwaveling
J
. 2020 . Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data . Eur J Endocrinol , 182 :131 –138 .
3.
Schlumberger
M
,
Tahara
M
,
Wirth
LJ
,
Robinson
B
,
Brose
MS
,
Elisei
R
,
Habra
MA
,
Newbold
K
,
Shah
MH
,
Hoff
AO
,
Gianoukakis
AG
,
Kiyota
N
,
Taylor
MH
,
Kim
SB
,
Krzyzanowska
MK
,
Dutcus
CE
,
de las Heras
B
,
Zhu
J
,
Sherman
SI
. 2015 . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer . N Engl J Med , 372 :621 –630 .